Encouraging Outcomes for Novel Therapy Targeting Drug-resistant Tuberculosis
Researchers have made a significant leap forward in the fight against drug-resistant tuberculosis (TB), according to a recent study published in
Read more
DISEASES
FDA Greenlights Iovance’s AMTAGVI™ as First T-cell Therapy for Solid Tumor Cancer
Iovance Biotherapeutics, Inc., a leading biotechnology firm specialising in pioneering, developing, and delivering advanced polyclonal tumor infiltrating lymphocyte (TIL) cell
Read more
Vaxart Awarded $9.27 Mill Funding for Phase 2b Trial of Oral Pill COVID-19 Vaccine
American clinical-stage biotechnology company Vaxart, Inc. has announced that the United States Biomedical Advanced Research and Development Authority (BARDA) granted
Read more
Phase 3 Trial Data Shows Novartis Lutathera® Effective as First-line Treatment for GEP-NETs
Lutathera®, developed by Swiss drugmaker Novartis has demonstrated a substantial 72% reduction in the risk of disease progression or death
Read more
Roche’s Tecentriq SC Becomes the EU’s First Approved Subcutaneous Injection PD-(L)1 Cancer Immunotherapy
The European Commission (EC) has granted marketing authorisation for Roche’s Tecentriq® SC (atezolizumab) making it the first European Union PD-(L)1
Read more
AbbVie Launches PRODUODOPA® in the EU for Advanced Parkinson’s Disease
AbbVie has introduced PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union to address advanced Parkinson’s disease. AbbVie (NYSE: ABBV) recently announced the
Read more
Bristol Myers Squibb Acquires Radiopharma Company RayzeBio
Bristol Myers Squibb has added a premier radiopharmaceutical platform to its portfolio with the acquisition of RayzeBio, a radiopharmaceutical therapeutics
Read more
Bristol Myers Squibb Enhances Neuroscience Portfolio Through $14 Billion Karuna Therapeutics Acquisition
American multinational pharmaceutical company Bristol Myers Squibb and Karuna Therapeutics, Inc. (“Karuna”) have announced that they have entered into a
Read more
Investigating the Connections Between Amyloid Beta and Alpha Synuclein in Neurodegenerative Diseases
Alzheimer’s disease (AD) and Parkinson’s disease (PD) stand as the two most prevalent neurodegenerative disorders, each characterized by the cerebral
Read more
AstraZeneca to Buy Gracell Advancing Cell Therapy Ambition
AstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read more